BACKGROUND: The relationships between immunovirological status, inflammatory markers, insulin resistance and fat distribution have not been studied in recently diagnosed (<1 year) antiretroviral-naive HIV-1-infected patients. METHODS: We studied 214 antiretroviral-naive patients at enrolment in the metabolic substudy of the ANRS COPANA cohort. We measured clinical, immunovirological and inflammatory parameters, glucose/insulin during oral glucose tolerance test (OGTT), adipokines, subcutaneous and visceral fat surfaces (subcutaneous adipose tissue [SAT] and visceral adipose tissue [VAT], assessed by computed tomography) and the body fat distribution based on dual-energy X-ray absorptiometry (DEXA). RESULTS: Median age was 36 years; 28% of the patients were female and 35% of sub-Saharan origin; 20% had low CD4(+) T-cell counts (≤200/mm(3)). Patients with low CD4(+) T-cell counts were older and more frequently of sub-Saharan Africa origin, had lower body mass index (BMI) but no different SAT/VAT ratio and fat distribution than other patients. They also had lower total, low-density lipoprotein and high-density lipoprotein cholesterolaemia, higher triglyceridaemia and post-OGTT glycaemia, higher markers of insulin resistance (insulin during OGTT and homeostasis model assessment of insulin resistance) and of inflammation (high-sensitivity C-reactive protein, IL-6, tumour necrosis factor (TNF)-α, sTNFR1 and sTNFR2). After adjustment for age, sex, geographic origin, BMI and waist circumference, increased insulin resistance was not related to any inflammatory marker. In multivariate analysis, low CD4(+) T-cell count was an independent risk factor for altered insulin sensitivity (β-coefficient for HOMA-IR: +0.90; P=0.001; CD4(+) T-cell count >500/mm(3) as the reference), in addition to older age (β: +0.26 for a 10-year increase; P=0.01) and higher BMI (β: +0.07 for a 1-kg/m(2) increase; P=0.003). CONCLUSIONS: In ART-naive patients, severe immune deficiency but not inflammation could be an early risk factor for altered insulin sensitivity.
BACKGROUND: The relationships between immunovirological status, inflammatory markers, insulin resistance and fat distribution have not been studied in recently diagnosed (<1 year) antiretroviral-naive HIV-1-infectedpatients. METHODS: We studied 214 antiretroviral-naive patients at enrolment in the metabolic substudy of the ANRS COPANA cohort. We measured clinical, immunovirological and inflammatory parameters, glucose/insulin during oral glucose tolerance test (OGTT), adipokines, subcutaneous and visceral fat surfaces (subcutaneous adipose tissue [SAT] and visceral adipose tissue [VAT], assessed by computed tomography) and the body fat distribution based on dual-energy X-ray absorptiometry (DEXA). RESULTS: Median age was 36 years; 28% of the patients were female and 35% of sub-Saharan origin; 20% had low CD4(+) T-cell counts (≤200/mm(3)). Patients with low CD4(+) T-cell counts were older and more frequently of sub-Saharan Africa origin, had lower body mass index (BMI) but no different SAT/VAT ratio and fat distribution than other patients. They also had lower total, low-density lipoprotein and high-density lipoprotein cholesterolaemia, higher triglyceridaemia and post-OGTT glycaemia, higher markers of insulin resistance (insulin during OGTT and homeostasis model assessment of insulin resistance) and of inflammation (high-sensitivity C-reactive protein, IL-6, tumour necrosis factor (TNF)-α, sTNFR1 and sTNFR2). After adjustment for age, sex, geographic origin, BMI and waist circumference, increased insulin resistance was not related to any inflammatory marker. In multivariate analysis, low CD4(+) T-cell count was an independent risk factor for altered insulin sensitivity (β-coefficient for HOMA-IR: +0.90; P=0.001; CD4(+) T-cell count >500/mm(3) as the reference), in addition to older age (β: +0.26 for a 10-year increase; P=0.01) and higher BMI (β: +0.07 for a 1-kg/m(2) increase; P=0.003). CONCLUSIONS: In ART-naive patients, severe immune deficiency but not inflammation could be an early risk factor for altered insulin sensitivity.
Authors: Todd T Brown; Stephen R Cole; Xiuhong Li; Lawrence A Kingsley; Frank J Palella; Sharon A Riddler; Barbara R Visscher; Joseph B Margolick; Adrian S Dobs Journal: Arch Intern Med Date: 2005-05-23
Authors: Todd T Brown; Xiuhong Li; Stephen R Cole; Lawrence A Kingsley; Frank J Palella; Sharon A Riddler; Joan S Chmiel; Barbara R Visscher; Joseph B Margolick; Adrian S Dobs Journal: AIDS Date: 2005-09-02 Impact factor: 4.177
Authors: M K Hellerstein; C Grunfeld; K Wu; M Christiansen; S Kaempfer; C Kletke; C H Shackleton Journal: J Clin Endocrinol Metab Date: 1993-03 Impact factor: 5.958
Authors: Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren Journal: N Engl J Med Date: 2007-04-26 Impact factor: 91.245
Authors: W M El-Sadr; J D Lundgren; J D Neaton; F Gordin; D Abrams; R C Arduino; A Babiker; W Burman; N Clumeck; C J Cohen; D Cohn; D Cooper; J Darbyshire; S Emery; G Fätkenheuer; B Gazzard; B Grund; J Hoy; K Klingman; M Losso; N Markowitz; J Neuhaus; A Phillips; C Rappoport Journal: N Engl J Med Date: 2006-11-30 Impact factor: 91.245
Authors: Eugene Mutimura; Donald R Hoover; Qiuhu Shi; Jean Claude Dusingize; Jean D'Amour Sinayobye; Mardge Cohen; Kathryn Anastos Journal: PLoS One Date: 2015-04-16 Impact factor: 3.240
Authors: Mark E Pepin; Lindsey E Padgett; Ruth E McDowell; Ashley R Burg; Manoja K Brahma; Cassie Holleman; Teayoun Kim; David Crossman; Olaf Kutsch; Hubert M Tse; Adam R Wende; Kirk M Habegger Journal: Mol Metab Date: 2018-04-20 Impact factor: 7.422
Authors: Cecilia M Shikuma; Dominic C Chow; Louie Mar A Gangcuangco; Guangxiang Zhang; Sheila M Keating; Philip J Norris; Todd B Seto; Nisha Parikh; Kalpana J Kallianpur; Beau K Nakamoto; Lorna S Nagamine; Lishomwa C Ndhlovu; Jason D Barbour Journal: PLoS One Date: 2014-02-27 Impact factor: 3.240